Self-reported and physiological reactions to the third BNT162b2 mRNA

2 COVID-19 (booster) vaccine dose

- 3 Running title: Reactions to the third Pfizer COVID-19 (booster) vaccine
- **dose** Merav Mofaz, MSc¹, Matan Yechezkel, MSc¹, Grace Guan², Margaret L. Brandeau, PhD², Tal
- 5 Patalon, MD³, Sivan Gazit, MD³, Dan Yamin, PhD^{1,4,+}, and Erez Shmueli, PhD^{1,5,+,*}
- 6 ¹Department of Industrial Engineering, Tel Aviv University, Tel Aviv, Israel.
- 7 ²Department of Management Science and Engineering, Stanford University, Stanford CA, USA.
- 8 ³Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv, Israel.
- ⁴Center for Combatting Pandemics, Tel Aviv University, Tel Aviv, Israel.
- ⁵MIT Media Lab, Cambridge MA, USA.
- 11 ⁺Equal contribution
- *Corresponding author. Email: shmueli@tau.ac.il
- 13 Keywords: COVID-19 vaccine, third COVID-19 dose, booster vaccine, BNT162b2, adverse effects,
- 14 wearables

1

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

Abstract **Background**: The rapid rise in hospitalizations associated with the Delta-driven COVID-19 resurgence, and the imminent risk of hospital overcrowding, led the Israeli government to initialize a national third (booster) COVID-19 vaccination campaign in early August 2021, offering the BNT162b2 mRNA vaccine to individuals who received their second dose over five months ago. However, the safety of the third (booster) dose has not been fully established yet. **Objective**: Evaluate the short-term, self-reported and physiological reactions to the third BNT162b2 mRNA COVID-19 (booster) vaccine dose. **Design**: A prospective observational study, in which participants are equipped with a smartwatch and fill in a daily questionnaire via a dedicated mobile application for a period of 21 days, starting seven days before the vaccination. **Setting**: An Israel-wide third (booster) vaccination campaign. Participants: A group of 1,609 (18+ years of age) recipients of at least one dose of the BNT162b2 vaccine between December 20, 2020, and September 15, 2021, out of a larger cohort of 2,912 prospective study participants. 1,344 of the participants were recipients of the third vaccine dose. **Measurements**: Daily self-reported questionnaires regarding local and systemic reactions, mood level, stress level, sport duration, and sleep quality. Heart rate, heart rate variability and blood oxygen saturation level were continuously measured by Garmin Vivosmart 4 smartwatches. Results: The extent of systemic reactions reported following the third (booster) dose

administration is similar to that reported following the second dose (p-value=0.305) and

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

considerably greater than that reported following the first dose (p-value<0.001). Our analyses of self-reported well-being indicators as well as the objective heart rate and heart rate variability measures recorded by the smartwatches further support this finding. Focusing on the third dose, reactions were more apparent in younger participants (pvalue<0.01), in women (p-value<0.001), and in participants with no underlying medical conditions (p-value<0.001). Nevertheless, reported reactions and changes in physiological measures returned to their baseline levels within three days from inoculation with the third dose. **Limitations**: Participants may not adequately represent the vaccinated population in Israel and elsewhere. **Conclusion**: Our work further supports the safety of a third COVID-19 BNT162b2 mRNA (booster) vaccine dose from both a subjective and an objective perspective, particularly in individuals 65+ years of age and those with underlying medical conditions. **Primary funding source**: European Research Council (ERC) project #949850. **Introduction:** The SARS-CoV-2 Delta variant (also termed variant B.1.617.2) was discovered in October

The SARS-CoV-2 Delta variant (also termed variant B.1.617.2) was discovered in October 2020, in India, and was designated as a variant of concern by the World Health Organization (WHO) in May 2021 (1–3). Since its discovery, it has spread worldwide and has rapidly become the most dominant variant in many countries (4–7). Although the BNT162b2 COVID-19 vaccine is highly effective against the Alpha variant (8), recent studies show that the effectiveness of the Pfizer-BioNTech vaccines is notably lower against the Delta variant – 88% compared to 93.7% against the Alpha variant (9–12).

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

Moreover, recent evidence shows that fully vaccinated individuals infected with the virus can easily transmit it further, as their peak viral burden is similar to that observed in unvaccinated individuals (7,10). In Israel, the Delta variant has accelerated COVID-19 infection and hospitalization, with numbers doubling every ten days between July 1, 2021 and August 9, 2021 (7,13), despite the high coverage of the BNT162b2 vaccine in Israel during this period—greater than 75% coverage with two Pfizer doses in the eligible population (individuals ≥ 12 years of age) (13). The rapid rise in hospitalizations associated with the Delta-driven COVID-19 resurgence, and the imminent risk of hospital overcrowding, led the Israeli government to initialize on July 30, 2021, an unparalleled, pro-active, national third (booster) vaccine shot campaign, offering the BNT162b2 mRNA COVID-19 vaccine to individuals over the age of 60. On August 13, 2021, the booster campaign was expanded to include those over 50 years of age, reaching 63% third-dose coverage among the eligible population within only 26 days (7,14–16). Two weeks later, on August 29, 2021, the campaign was expanded to include all individuals 16+ of age, demanding only that five months have passed since the receipt of the second dose, reaching 40% third-dose coverage among the eligible population under 50 years of age, within 16 days (13,17). Currently, limited information is available on the safety of a BNT162b2 third dose (18,19), with such a booster vaccine yet to be authorized by the US Food and Drug Administration (FDA) to the general population (20). While recent evidence shows that a third BNT162b2 dose in immunocompromised individuals has a favorable safety profile (19,21), the safety of a third (booster) dose in the general population has not yet been fully established.

Here, we evaluate the short-term effects of a third BNT162b2 mRNA COVID-19 vaccine dose on self-reported and physiological indicators. We followed a cohort of 2,912 participants; of these, 1,609 participants received at least one dose of the BNT162b2 vaccine after joining the study. Each participant received a dedicated mobile application and a Garmin Vivosmart 4 smartwatch. The mobile application collected daily self-reported questionnaires on local and systemic reactions as well as various well-being indicators. The smartwatch continuously monitored several physiological measures, including heart rate, heart rate variability (HRV) and blood oxygen saturation level. Our analysis of the comprehensive data on each participant examines the safety of a third (booster) vaccine dose from both a subjective perspective (patient questionnaire) and an objective perspective (smartwatch data).

Materials and Methods

Study design and participants

Our study includes a prospective cohort of 2,912 participants (18+ years of age) who were recruited between November 1, 2020 and September 15, 2021. The 1,609 participants who reported receipt of at least one of the three BNT162b2 mRNA COVID-19 vaccine shots after joining the study served as the base cohort for our analysis. Specifically, of these 1,609 participants, during the study, 223 received their first dose, 351 their second dose, and 1,344 their third dose.

We employed a professional survey company to recruit participants and ensure they follow through with the study requirements. Participant recruitment was performed via advertisements on social media and word-of-mouth. Each participant provided informed consent by signing a form after receiving a comprehensive explanation on the study. Then, participants completed a one-time enrollment questionnaire, were equipped with Garmin Vivosmart 4 smartwatches, and installed two applications on their mobile phones: (1) the PerMed application (22) that collected daily self-reported questionnaires, and (2) an application that passively recorded the smartwatch data. Participants were asked to wear their smartwatches as much as possible. The survey company ensured that participants' questionnaires were completed daily, that their smartwatches were charged and properly worn, and that any technical problems with the mobile applications or smartwatch were resolved.

PerMed mobile application

Participants used the PerMed mobile application (22) to fill out daily questionnaires. The questionnaire allowed participants to report various well-being indicators, including mood level (on a scale of 1 [awful] to 5 [excellent]), stress level (on a scale of 1 [very low] to 5 [very high]), sport duration (in minutes), and sleep quality (on a scale of 1 [awful] to 5 [excellent]). The questionnaire also collected data on clinical symptoms consistent with the local and systemic reactions observed in the BNT162b2 mRNA Covid-19 clinical trial (23), with an option to add other symptoms as free text. (For more details see Appendix A in the Supplemental Material)

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

We implemented preventive measures to improve the quality, continuity, and reliability of the collected data. Each day, if by 7 pm, participants had not yet filled out the daily questionnaire, they received a reminder notification through the PerMed application. Furthermore, we used a dedicated dashboard to identify participants who continually neglected to complete the daily questionnaires; these participants were contacted by the survey company and were encouraged to better adhere to the study protocol. The smartwatch Participants were equipped with Garmin Vivosmart 4 smart fitness trackers. Among other features, the smartwatch provides all-day heart rate and heart rate variability and duringnight blood oxygen saturation level tracking capabilities (24). The optical wrist heart rate (HR) monitor of the smartwatch is designed to continuously monitor a user's heart rate. The frequency at which heart rate is measured varies and may depend on the level of activity of the user: when the user starts an activity, the optical HR monitor's measurement frequency increases. Since heart rate variability (HRV) is not easily accessible through Garmin's application programming interface (API), we use Garmin's stress level instead, which is calculated based on HRV. Specifically, the device uses heart rate data to determine the interval between each heartbeat. The variable length of time between each heartbeat is regulated by

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

the body's autonomic nervous system. Less variability between beats correlates with higher stress levels, whereas an increase in variability indicates less stress (25). A similar relationship between HRV and stress was also seen in (26,27). The Pulse Ox monitor of the smartwatch uses a combination of red and infrared lights with sensors on the back of the device to estimate the percentage of oxygenated blood (peripheral oxygen saturation, SpO2%). The Pulse Ox monitor is activated each day at a fixed time for a period of four hours (the default is 2AM-6AM). Examining the data collected in our study, we identified an HR sample roughly every 15 seconds, an HRV sample every 180 seconds, and an SpO2 sample every 60 seconds. While the Garmin smartwatch provides state-of-the-art wrist monitoring, it is not a medical-grade device, and some readings may be inaccurate under certain circumstances, depending on factors such as the fit of the device and the type and intensity of the activity undertaken by a participant (28–30). **Statistical analysis** Questionnaire data were preprocessed by manually categorizing any self-reported symptom entered as free text. In addition, if participants filled out the questionnaire more than once in one day, the last entry from that day was used in the analysis. Smartwatch data were preprocessed as follows. First, we computed the mean value of each hour of data. We

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

then performed linear interpolation to impute missing hourly means. Lastly, we smoothed the data by calculating the five-hour moving average. For each participant, we defined the 7-day period prior to vaccination as the baseline period. We noted any pre-existing clinical symptoms from the last questionnaire completed during the baseline period. Next, we calculated the percentage of participants who reported new (that is, not pre-existing) systemic reactions in the 48 hours after vaccination. For each reaction, we used a beta distribution to determine a 90% confidence interval. To determine the statistical significance of differences between the first and third doses and between the second and third doses as reflected by the extent of reported reactions, a two proportion Ztest was used. We also calculated the mean difference in well-being indicators between the postvaccination period and the baseline period. Specifically, for each indicator, for each of the three days post-vaccination, and for each participant, we calculated the difference between that indicator's value and its corresponding value in the baseline period. Then, we calculated the mean value over all participants and the associated 90% confidence interval. To compare the changes in smartwatch physiological indicators over the seven days (168) hours) post vaccination with those of the baseline period, we performed the following steps. First, for each participant and each hour during the seven days post vaccination, we calculated the difference between that hour's indicator value and that of the corresponding hour in the baseline period (keeping the same day of the week and same hour during the

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

day). Then, we aggregated each hour's differences over all participants to calculate a mean difference and associated 90% confidence interval, which is analogous to a one-sided t-test with significance level 0.05. To determine the statistical significance of differences between the first and third doses and between the second and third doses as reflected by changes in smartwatch indicators during the 48 hours post-vaccination, we used a twosample t-test with unequal variance. We repeated the above analyses for the third dose stratified by age groups (<50, 50-64, and ≥65), gender and the existence of an underlying medical condition (present vs. not present) from the list specified in Table 1. **Ethical Approval** Before participating in the study, all subjects were advised, both orally and in writing, as to the nature of the study and gave written informed consent. The study was approved by MHS' Helsinki institutional review board, protocol number 0122-20-MHS. Results Of the 1,609 participants who received at least one dose of the BNT162b2 vaccine after joining the study, 854 (53.08%) were women, and 755 (46.92%) were men. Their age ranged between 18 and 88 years, with a median age of 52 (Table 1). 1,258 (78.19%) participants had a body mass index below 30, and 412 (25.61%) had at least one specific underlying medical condition (Table 1). The distributions of age and gender and the existence of underlying medical conditions were relatively invariable across the recipients of the first, second and third dose (Table 1).

Table 1. Characteristics of the participants

219

220

221

Characteristic	All Participants	First Dose	Second Dose	Third Dose
	(N=1,609)	(N=223)	(N=351)	(N=1,344)
Gender				
Male	46.92% (755)	45.29%	45.58% (160)	47.54% (639)
		(101)		
Female	53.08% (854)	54.71%	54.42% (191)	52.46% (705)
		(122)		
Age group				
18-29 yr	14.23% (229)	6.28% (14)	11.11% (39)	14.06% (189)
30-39 yr	16.9% (272)	4.93% (11)	15.1% (53)	16.29% (219)
40-49 yr	11.0% (177)	6.73% (15)	11.97% (42)	10.27% (138)
50-59 yr	26.1% (420)	28.7% (64)	24.79% (87)	27.9% (375)
60-69 yr	22.25% (358)	31.39% (70)	21.37% (75)	22.92% (308)
≥ 70 yr	9.51% (153)	21.97% (49)	15.67% (55)	8.56% (115)
Body-mass index*				
< 30.0	78.19% (1,258)	78.48%	79.77% (280)	77.68% (1,044)
		(175)		
≥ 30.0	20.51% (330)	18.39% (41)	17.09% (60)	21.43% (288)
Unspecified	1.31% (21)	3.14% (7)	3.13% (11)	0.89% (12)
Underlying Medical Cor	ndition			
Hypertension	14.17% (228)	20.63% (46)	15.95% (56)	14.43% (194)

Diabetes	8.64% (139)	13% (29)	7.98% (28)	8.41% (113)
Heart disease	4.79% (77)	7.17% (16)	4.56% (16)	4.99% (67)
Chronic lung disease	5.03% (81)	4.93% (11)	3.7% (13)	5.21% (70)
Immune suppression	0.81% (13)	1.35% (3)	0.85% (3)	0.89% (12)
Cancer	0.62% (10)	0.45% (1)	0.57% (2)	0.67% (9)
Renal failure	0.5% (8)	1.79% (4)	1.42% (5)	0.45% (6)
None of the above	73.34% (1,180)	64.57%	72.08% (253)	73.21% (984)
		(144)		
Unspecified	1.06% (17)	1.35% (3)	2.85% (10)	0.52% (7)

^{*} The body-mass index is the weight in kilograms divided by the square of the height in meters

Our examination of self-reported reactions revealed that the extent of systemic reactions reported following the third vaccine dose are similar to those reported following the second dose (p-value=0.305), and considerably greater than those observed following the first dose (p-value<0.001) (Figure 1). Specifically, 60.4% (90% CI: 57.9-62.9%) of the participants did not report any new symptoms after receiving the third dose, compared to 86.5% (90% CI: 81.9-91.0%) and 63.6% (90% CI: 59.1-67.8%) after the first and second doses, respectively. Moreover, the most frequently reported types of reactions—fatigue, headache, muscle pain, fever, and chills—were similar after the second and third doses. These reactions faded in nearly all participants within three days (Figure S8 in the Supplemental Material). Notably, these trends are consistent with those reported in the first and second dose BNT162b2 mRNA vaccine clinical trial (23).




Figure 1. Reactions reported by participants through the mobile application. The bars represent the percentage of participants who reported a given symptom. Error bars represent 90% confidence intervals.

For the self-reported well-being indicators (Fig. 2), we found that during the first two days after the third vaccine dose, participants exhibited a significant reduction in mood level (Fig. 2A), sport duration (Fig. 2C), sleep quality (Fig. 2D) and a notable increase in stress level (Fig. 2B) compared to baseline levels. These changes faded away on the third day post vaccination. A similar trend can be observed after the second vaccine dose, except for the reported stress level that remains below the baseline level during the second and third days post-vaccination.




Figure 2. Changes in subjective well-being indicators reported by participants through the mobile application. Mean difference compared to baseline levels for the well-being indicators of (A) Mood level, (B) Stress level, (C) Sport duration, and (D) Sleep quality. Mood level, Stress level, and Sleep quality were reported on a 1-5 Likert scale. Sport duration was measured in minutes. Error bars represent 90% confidence intervals. Horizontal dashed lines represent no change compared to baseline levels.

We observed similar trends when analyzing the objective and continuous physiological measurements collected by the smartwatch (Fig. 3 below and Fig. S1 in the Supplemental Material). Specifically, we identified a considerable rise in both the heart rate (Fig. 3A-C) and the heart rate variability-based stress (Fig. 3D-F) indicators in the first 48 hours following the administration of the third dose. Measurements returned to their baseline levels within 72 hours. By contrast, our analysis of blood oxygen saturation levels suggests

that there are no apparent changes following inoculation compared to baseline levels (Fig. 3G-I). The trends observed for the objective heart rate (HR) and heart rate variability (HRV) indicators were consistent with those of the subjective indicators in the following sense - similar changes following the second and third doses (HR p-value=0.43, HRV p-value=0.28), and greater changes following the second and third doses than the first dose (HR p-value<0.03, HRV p-value<0.01).




Figure 3. Changes in objective physiological indicators measured through the smartwatch. Mean difference in smartwatch-recorded (**A-C**) heart rate, (**D-F**) heart rate variability-based stress and (**G-I**) blood oxygen saturation level (SpO2) following the first, second and third dose, compared to their baseline levels. Mean values are depicted as solid lines; 90% confidence intervals

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292


293

294

295

are presented as shaded regions. The horizontal dashed line represents no change compared to the baseline levels, and vertical lines represent 24-hour periods. We also stratified our analyses of well-being and smartwatch physiological indicators after the third vaccination by age group, gender, and the existence of a prior underlying medical condition (Fig. 4 below and Fig. S2-S7 in the Supplemental Material). For all stratifications, trends were similar to those observed in the general population. Namely, there were considerable changes in the two days after vaccine administration that faded almost entirely after three days. We also found that participants 65+ years reported fewer reactions (p-value<0.001) and exhibited milder physiological changes compared to those between 50-65 years (HR p-value=0.02, HRV p-value=0.07), and participants between 50-65 years reported even fewer reactions (p-value<0.01) and exhibited milder physiological changes in heart rate (HR p-value=0.02), compared to those below 50 years (Figure 4A-B). Male participants reported fewer reactions (p-value<0.001) but did not exhibit milder physiological changes (HR p-value=0.37, HRV p-value=0.59) than female participants. Participants with an underlying medical condition reported fewer reactions (pvalue<0.001) and exhibited milder physiological changes (HR p-value=0.04, HRV pvalue=0.16), compared to those without an underlying medical condition. Markedly, out of 9 participants who reported dyspnea 4 (0.96% of their age group) were below 50 years, 4 (0.93% of their age group) were between 50-64 years and 1 (0.65% of her age group) was 65+ years. One participant below 50 years reported chest pain following inoculation. None of these participants had underlying medical condition. These reactions (i.e., dyspnea

and chest pain) disappeared between 2-4 days following inoculation.



age, gender and the existence of an underlying medical condition. Reactions reported by participants through the mobile application, stratified by age (A), gender (B) and underlying medical condition (E). The bars represent the percentage of participants who reported a given symptom. Error bars represent 90% confidence intervals. Changes in objective heart rate and heart rate variability measured through the smartwatch in the 48 hours post-vaccination, stratified by age (B), gender (D) and underlying medical condition (F).

Discussion

Our key findings suggest that local and systemic reactions reported following the third (booster) vaccine dose administration are very similar to those reported following the second dose and considerably greater than those observed following the first dose. Our

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

analyses of both self-reported well-being indicators and objective smartwatch physiological indicators underscore these results. Furthermore, within three days from inoculation with the third dose, all measures returned to their baseline levels in nearly all participants. We identified differences in subpopulations based on gender, age and underlying medical condition following administration of the third vaccine dose. It has been previously suggested that reactions caused by the COVID-19 vaccine are a byproduct of a short burst of IFN-I generation concomitant with induction of an effective immune response (31). IFN-I generation is substantially stronger in females than in males and stronger in younger and healthier individuals than in older and less healthy ones. We found that participants below the age of 65, females, and those without an underlying medical condition experienced greater reactions both in self-reported local and systemic reactions and well-being indicators as well as in objective physiological measurements recorded by the smartwatch. Our results are also in line with a previous study that found similar trends after the first and second doses (32). Clinical trials have not yet capitalized on the comprehensive physiological measures generated by wearables. Currently, the FDA and European Medicines Agency (EMA) evaluate the safety and create guidelines for newly developed vaccines primarily based on subjective, self-reported questionnaires (33,34). Much of the scientific literature discusses these self-reported side effects of COVID-19 vaccines. However, integrating wearables

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

into clinical trials, alongside self-reported questionnaires, can provide more precise and rich data regarding the vaccines' effects on physiological measures. Our study has several limitations. First, the 1,609 individuals who comprise the base cohort of our analyses may not be representative of the vaccinated population in Israel or globally. Nevertheless, the changes observed in self-reported reactions and well-being indicators as well as objective physiological indicators recorded by the smartwatches were statistically significant and consistent with each other. Moreover, the reaction types, frequency and duration we observed for the first and second dose were similar to those observed in the BNT162b2 mRNA vaccine clinical trials (23). In addition, a clear pattern of returning to baseline levels was observed within 72 hours post inoculation in all examined measures. Lastly, although the sample size was limited, trends were consistent regardless of age group, gender, and the existence of underlying medical conditions. Second, we did not explicitly control for the effects of the observational trial setting (i.e., participating in a trial, wearing a smartwatch, potential concerns regarding the vaccine, etc.). Any effects of the observational trial setting should, in principle, have similar impacts on our analysis of each of the three vaccine doses. However, since we found no deviations in most measurements from baseline levels in the subset of participants who received their first dose, we believe the changes observed after the second and third doses arise from an actual reaction to the vaccine.

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

Third, the smartwatches used to obtain physiological measurements are not medical-grade devices. Nevertheless, recent studies show a considerably accurate heart rate measurement in the previous versions of the smartwatch used in this study (28,29). Moreover, our analysis focused on the change in measurements compared to their baseline values rather than on their absolute values. Finally, the only vaccine available in Israel is the BNT162b2 mRNA vaccine. Although our findings may not directly generalize to other types of COVID-19 vaccines, we believe that applying our analyses on other vaccines are likely to yield qualitatively similar findings, due to the similarities observed between different COVID-19 vaccines (23,35,36).Our study strengthens the evidence regarding the short-term safety of the booster BNT162b2 vaccine in several ways. First, reports of local and systemic reactions following the third dose were very similar to those observed following the second dose, which was already shown in clinical trials to be safe (23). Second, the considerable changes observed in all indicators during the first two days after receiving the third vaccine, including selfreported reactions and well-being indicators as well as objective physiological indicators collected by the smartwatch, returned to their baseline levels. Third, regardless of the observed differences between subpopulations, our analyses indicate a clear pattern of return to baseline levels in all considered subpopulations. Fourth, we observed no change in blood oxygen saturation levels compared to baseline levels, indicating that major adverse health consequences are less likely.

In conclusion, our study supports the short-term safety of the third BNT162b2 mRNA COVID-19 (booster) vaccine dose and mitigates, in part, concerns regarding its short-term effects. The medical and scientific communities could greatly benefit from the largely unbiased data generated by digital health technologies such as the wearable data which we analyzed in this study. Our findings could also be of interest to public health officials and other stakeholders, as it is important that objective measures are given attention in the critical evaluation of clinical trials.

References 383 384 1. Kupferschmidt K, Wadman M. Delta variant triggers new phase in the pandemic. 385 Science (80-) [Internet]. 2021 Jun 25 [cited 2021 Aug 22];372(6549):1375–6. Available from: https://science.sciencemag.org/content/372/6549/1375 386 2. Tracking SARS-CoV-2 variants [Internet]. [cited 2021 Aug 22]. Available from: 387 https://www.who.int/en/activities/tracking-SARS-CoV-2-variants 388 3. 389 Mlcochova P, Kemp S, Dhar MS, Papa G, Meng B, Mishra S, et al. SARS-CoV-2 390 B.1.617.2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthrough. bioRxiv [Internet]. 2021 Aug 6 [cited 2021 Aug 391 392 22];2021.05.08.443253. Available from: 393 https://www.biorxiv.org/content/10.1101/2021.05.08.443253v5 Delta Variant: What We Know About the Science | CDC [Internet]. [cited 2021 394 4. 395 Aug 22]. Available from: https://www.cdc.gov/coronavirus/2019ncov/variants/delta-variant.html 396 397 5. Mahase E. Delta variant: What is happening with transmission, hospital admissions, and restrictions? BMJ [Internet]. 2021 Jun 15 [cited 2021 Aug 398 399 22];373:n1513. Available from: https://www.bmj.com/content/373/bmj.n1513 400 6. Weekly epidemiological update on COVID-19 - 17 August 2021 [Internet]. [cited 401 2021 Aug 22]. Available from: https://www.who.int/publications/m/item/weeklyepidemiological-update-on-covid-19---17-august-2021 402

Wadman M. Israel's grim warning: Delta can overwhelm shots. Science (80-)

403

7.

[Internet]. 2021 Aug 20 [cited 2021 Aug 22];373(6557):838–9. Available from: 404 https://science.sciencemag.org/content/373/6557/838 405 406 8. Munitz A, Yechezkel M, Dickstein Y, Yamin D, Gerlic M. BNT162b2 vaccination 407 effectively prevents the rapid rise of SARS-CoV-2 variant B.1.1.7 in high-risk populations in Israel. Cell Reports Med [Internet]. 2021 Apr [cited 2021 May 408 409 3];0(0):100264. Available from: https://linkinghub.elsevier.com/retrieve/pii/S266637912100080X 410 Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. 411 9. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. 412 413 https://doi.org/101056/NEJMoa2108891 [Internet]. 2021 Jul 21 [cited 2021 Aug 22];385(7):585–94. Available from: 414 https://www.nejm.org/doi/full/10.1056/NEJMoa2108891 415 10. Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta K-D, et al. 416 Impact of Delta on viral burden and vaccine effectiveness against new SARS-417 CoV-2 infections in the UK. 418 419 11. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. 420 421 Lancet [Internet]. 2021 Jun 26 [cited 2021 Aug 22];397(10293):2461-2. Available from: http://www.thelancet.com/article/S0140673621013581/fulltext 422 Nasreen S, He Msc S, Mph HC, Brown Phd KA, Gubbay JB, Buchan SA, et al. 423 12. 424 Effectiveness of COVID-19 vaccines against variants of concern, Canada on behalf of the Canadian Immunization Research Network (CIRN) Provincial 425

Collaborative Network (PCN) Investigators. [cited 2021 Aug 22]; Available from: 426 https://doi.org/10.1101/2021.06.28.21259420 427 428 13. COVID-19 Datasets- Government Data [Internet]. [cited 2020 May 30]. Available 429 from: https://data.gov.il/dataset/covid-19 14. The Ministry of Health Director General Has Approved the Recommendation to 430 Administer a Third Vaccine Doe to 50-Year-Olds and Older and to Other 431 Populations | Ministry of Health [Internet], [cited 2021 Aug 22], Available from: 432 433 https://www.gov.il/en/departments/news/13082021-01 434 15. The Vaccination Advisory Committee Presented Data and Recommended the 435 Administration of a Third Dose to Older Adults | Ministry of Health [Internet]. [cited 2021 Aug 22]. Available from: 436 https://www.gov.il/en/departments/news/29072021-04 437 438 16. Statement by PM Bennett on Third Dose of the COVID Vaccine to Israeli Citizens over the Age of 60 | Prime Minister's Office [Internet]. [cited 2021 Aug 22]. 439 Available from: https://www.gov.il/en/Departments/news/event_press290721 440 17. The Vaccination Policy and the New Green Pass that will Take Effect Soon | 441 442 Ministry of Health [Internet]. [cited 2021 Sep 15]. Available from: 443 https://www.gov.il/en/departments/news/29082021-01 Joint Statement from HHS Public Health and Medical Experts on COVID-19 444 18. Booster Shots | CDC Online Newsroom | CDC [Internet]. [cited 2021 Aug 22]. 445 Available from: https://www.cdc.gov/media/releases/2021/s0818-covid-19-446 booster-shots.html 447

19. COVID-19 Vaccines for Moderately to Severely Immunocompromised People 448 CDC [Internet]. [cited 2021 Aug 22]. Available from: 449 450 https://www.cdc.gov/coronavirus/2019ncov/vaccines/recommendations/immuno.html 451 Joint Statement from HHS Public Health and Medical Experts on COVID-19 452 20. 453 Booster Shots | FDA [Internet]. [cited 2021 Aug 23]. Available from: 454 https://www.fda.gov/news-events/press-announcements/joint-statement-hhspublic-health-and-medical-experts-covid-19-booster-shots 455 Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Bello A Del. Three Doses of 456 21. an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. 457 458 https://doi.org/101056/NEJMc2108861 [Internet]. 2021 Jun 23 [cited 2021 Aug 459 23];385(7):661–2. Available from: https://www.nejm.org/doi/10.1056/NEJMc2108861 460 22. Oved S, Mofaz M, Lan A, Einat H, Kronfeld-Schor N, Yamin D, et al. Differential 461 462 effects of COVID-19 lockdowns on well-being: interaction between age, gender 463 and chronotype [Internet]. 2021 Jan [cited 2021 Mar 31]. Available from: https://www.researchsquare.com 464 23. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety 465 and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 466 [Internet]. 2020 Dec 31 [cited 2021 Mar 31];383(27):2603–15. Available from: 467 468 http://www.nejm.org/doi/10.1056/NEJMoa2034577 VÍVOSMART ® 4 Owner's Manual. 2018 [cited 2021 Aug 23]; Available from: 469 24.

470 www.garmin.com 471 25. What Is the Stress Level Feature on My Garmin Watch? | Garmin Support 472 [Internet]. [cited 2021 Aug 24]. Available from: https://support.garmin.com/en-473 US/?faq=WT9BmhjacO4ZpxbCc0EKn9 474 26. Kim H-G, Cheon E-J, Bai D-S, Lee YH, Koo B-H. Stress and Heart Rate Variability: A Meta-Analysis and Review of the Literature. Psychiatry Investig 475 [Internet]. 2018 Mar 1 [cited 2021 Aug 24];15(3):235. Available from: 476 477 /pmc/articles/PMC5900369/ 478 27. Pereira T, Almeida PR, Cunha JPS, Aguiar A. Heart rate variability metrics for 479 fine-grained stress level assessment. Comput Methods Programs Biomed. 2017 Sep 1;148:71–80. 480 RK R, R P, DP Z, B S, J EY, E D, et al. Accuracy of Wrist-Worn Activity 481 28. 482 Monitors During Common Daily Physical Activities and Types of Structured Exercise: Evaluation Study. JMIR mHealth uHealth [Internet]. 2018 Dec 1 [cited 483 2021 Aug 23];6(12). Available from: https://pubmed.ncbi.nlm.nih.gov/30530451/ 484 485 29. Bent B, Goldstein BA, Kibbe WA, Dunn JP. Investigating sources of inaccuracy in 486 wearable optical heart rate sensors. npj Digit Med 2020 31 [Internet]. 2020 Feb 10 487 [cited 2021 Aug 23];3(1):1–9. Available from: https://www.nature.com/articles/s41746-020-0226-6 488 30. Accuracy | Garmin [Internet]. [cited 2021 Aug 22]. Available from: 489 https://www.garmin.com/en-US/legal/atdisclaimer/ 490

491 31. Bunders MJ, Altfeld M. Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions. Immunity. 2020 Sep 492 493 15;53(3):487–95. 494 32. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine sideeffects and SARS-CoV-2 infection after vaccination in users of the COVID 495 496 Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis [Internet]. 2021 Jul 1 [cited 2021 Aug 24];21(7):939–49. Available from: 497 http://www.thelancet.com/article/S1473309921002243/fulltext 498 33. Development and Licensure of Vaccines to Prevent COVID-19 | FDA [Internet]. 499 [cited 2021 Mar 31]. Available from: https://www.fda.gov/regulatory-500 501 information/search-fda-guidance-documents/development-and-licensure-vaccinesprevent-covid-19 502 503 34. Clinical trials in human medicines | European Medicines Agency [Internet]. [cited 2021 Aug 23]. Available from: https://www.ema.europa.eu/en/human-504 regulatory/research-development/clinical-trials-human-medicines 505 506 35. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med [Internet]. 507 508 2021 Feb 4 [cited 2021 Mar 31];384(5):403–16. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2035389 509 510 Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. 36. 511 Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South 512

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

Africa, and the UK. Lancet [Internet]. 2021 Jan 9 [cited 2021 Mar 31];397(10269):99–111. Available from: https://doi.org/10.1016/ **Financial Support** This research was supported by the European Research Council (ERC) project #949850 and the Israel Science Foundation (ISF), grant No. 3409/19, within the Israel Precision Medicine Partnership program. MLB and GG received support from the Koret foundation grant for Smart Cities and Digital Living 2030. **Data availability** Researchers interested in obtaining an aggregated version of the data sufficient to reproduce the results reported in this paper should contact the corresponding author. **Authors' contributions** Conception and design: DY, ES. Collection and assembly of data: MM, TP, SG, ES. Analysis and interpretation of the data: MM, GG, MLB, DY, ES. Statistical expertise: MM, DY, ES. Drafting the article: MM, MY, DY, ES. Critical revision of the article for important intellectual content: DY, ES. Final approval of the article: All authors. Obtaining funding: DY, ES. **Disclosures** All authors have disclosed no conflicts of interest.

Reproducible Research Statement

536

- Further details are available from Dr. Erez Shmueli (e-mail, shmueli@tau.ac.il).
- 538 Statistical code will be available after acceptance.

*Corresponding author. Email: shmueli@tau.ac.il

Supplementary Materials for:

Self-reported and physiological reactions to the third BNT162b2 mRNA

COVID-19 (booster) vaccine dose

Merav Mofaz, MSc¹, Matan Yechezkel, MSc¹, Grace Guan², Margaret L. Brandeau, PhD², Tal Patalon, MD³, Sivan Gazit, MD³, Dan Yamin, PhD¹.⁴, and Erez Shmueli, PhD¹.⁵,+,*

¹Department of Industrial Engineering, Tel Aviv University, Tel Aviv, Israel.

²Department of Management Science and Engineering, Stanford University, Stanford CA, USA.

³Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv, Israel.

⁴Center for Combatting Pandemics, Tel Aviv University, Tel Aviv, Israel.

⁵MIT Media Lab, Cambridge MA, USA.

⁴Equal contribution

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

Appendix A: Self-reported questionnairs Enrollment questionnaire All participants will fill a one-time enrollment questionnaire that includes demographic questions and questions about the participant's health condition in general. Specifically, the questionnaire will include the following: age, gender, height, weight and underlying medical conditions (Listed in Table 1, main text). Other questions such as name, address, phone number and email will be recorded and used by the survey company to contact the participants. The answers will be filled-in directly by the survey company to the study's secured dashboard. Vaccination questionnaire The vaccination questionnaire we will use includes the following question: o COVID-19 vaccination – date, time and dose number. Daily questionnaire All participants will complete the daily self-reported questionnaire in a dedicated application (the PerMed mobile application). The daily questionnaire we will use includes the following questions: How is your mood today? • Awful (1) • Bad (2) • OK (3) • Good (4) • Excellent (5) How would you describe the level of your stress during the last day? • Very Low (1) • Low (2) • Medium (3) • High (4) • Very high (5) How would you define your last night sleep quality? • Awful (1) • Bad (2) • OK (3) • Good (4) • Excellent (5) o Try to remember how many minutes of sports activity you performed on the last day?

Have you experienced one or more of the following symptoms in the last 24 hours? • My general feeling is good, and I have no symptoms • Heat measured above 37.5 • Cough • Sore throat • Runny nose • Headache • Shortness of breath • Muscle aches • Weakness / fatigue • Diarrhea • Nausea / vomiting • Chills • Confusion • Loss of sense of taste / smell • Other symptom.

Appendix B: Additional Results

Changes in objective physiological indicators measured through the smartwatch following the three vaccine doses

Changes in objective physiological indicators observed during the first two days after the second and third vaccine doses are similar, and considerably greater than those observed following the first dose.




Figure S1. Changes in objective physiological indicators measured through the smartwatch during the first two days after vaccine. Mean difference in smartwatch-recorded heart rate and heart rate variability-based following the first, second and third dose, compared to their baseline levels. Changes in objective physiological indicators were calculated by subtracting the baseline values from the mean value of the first two days following the vaccine dose. Error bars represent 90% confidence intervals.

Changes in reported well-being indicators – stratification by age group

Changes in well-being observed during the first two days after the third vaccine dose were found to be higher for participants younger than 50 years compared to those between 50 and 65 years, and consequently higher than those older than 65 years, with the exception of reported stress level (Figure S2).




Figure S2. Changes in well-being indicators reported by participants through the mobile application stratified by age group. (A) mood level, measured on a 1-to-5 Likert scale. (B) Stress level, measured on a 1-to-5 Likert scale. (C) Sport duration, measured in minutes. (D) Sleep quality, measured on a 1-to-5 Likert scale. Changes in well-being indicators were calculated by subtracting the baseline values from the daily values. Error bars represent 90% confidence intervals. Horizontal dashed lines represent no change compared to baseline levels.

Changes in reported well-being indicators – stratification by gender

Changes in well-being observed during the first two days after the third vaccine dose were found to be similar for males and females (Figure S3).




Figure S3. Changes in well-being indicators reported by participants through the mobile application stratified by gender. (A) mood level, measured on a 1-to-5 Likert scale. (B) Stress level, measured on a 1-to-5 Likert scale. (C) Sport duration, measured in minutes. (D) Sleep quality, measured on a 1-to-5 Likert scale. Changes in well-being indicators were calculated by subtracting the baseline values from the daily values. Error bars represent 90% confidence intervals. Horizontal dashed lines represent no change compared to baseline levels.

Changes in reported well-being indicators – stratification by underlying medical condition Changes in mood level and sleep quality observed during the first two days after the third vaccine dose were found to be higher for participants without underlying medical conditions compared to those with underlying medical condition (Figure S4).




Figure S4. Changes in well-being indicators reported by participants through the mobile application stratified by underlying medical conditions. (A) mood level, measured on a 1-to-5 Likert scale. (B) Stress level, measured on a 1-to-5 Likert scale. (C) Sport duration, measured in minutes. (D) Sleep quality, measured on a 1-to-5 Likert scale. Changes in well-being indicators were calculated by subtracting the baseline values from the daily values. Error bars represent 90% confidence intervals. Horizontal dashed lines represent no change compared to baseline levels.

Changes in physiological indicators – stratification by age group

Changes in physiological indicators after the third vaccine dose stratified by age group were consistent with those observed in the general population (considerable changes during the first two days after vaccine administration that faded nearly entirely after three days). These changes were found to be higher for participants younger than 50 years compared to those between 50 and 65 years, and consequently higher than those older than 65 years (Figure S5).




Figure S5. Changes in physiological indicators measured through the smartwatch stratified by age groups. Mean difference in heart rate and heart rate variability-based stress indicators following the third dose, recorded by a smartwatch, compared to their baseline levels: (A and B) heart rate, (C and D) heart rate variability-based stress. Mean values are depicted as solid lines; 90% confidence intervals are presented as shaded regions. The horizontal dashed line represents no change compared to the baseline levels, and vertical lines represent 24-hour periods.

Changes in physiological indicators – stratification by gender

Changes in physiological indicators after the third vaccine dose stratified by gender were consistent with those observed in the general population (considerable changes during the first two days after vaccine administration that faded nearly entirely after three days). These changes were found to be higher for females compared to males (Figure S6).




Figure S6. Changes in physiological indicators measured through the smartwatch stratified by gender. Mean difference in heart rate and heart rate variability-based stress indicators following the third dose, recorded by a smartwatch, compared to their baseline levels: (**A** and **B**) heart rate, (**C** and **D**) heart rate variability-based stress. Mean values are depicted as solid lines; 90% confidence intervals are presented as shaded regions. The horizontal dashed line represents no change compared to the baseline levels, and vertical lines represent 24-hour periods.

Changes in physiological indicators – stratification by underlying medical condition

Changes in physiological indicators after the third vaccine dose stratified by underlying medical condition were consistent with those observed in the general population (considerable changes during the first two days after vaccine administration that faded nearly entirely after three days). These changes were found to be higher for participants without underlying medical conditions compared to those with underlying medical condition (Figure S7).




Figure S7. Changes in physiological indicators measured through the smartwatch stratified by underlying medical conditions. Mean difference in heart rate and heart rate variability-based stress indicators following the third dose, recorded by a smartwatch, compared to their baseline levels: (A and B) heart rate, (C and D) heart rate variability-based stress. Mean values are depicted as solid lines; 90% confidence intervals are presented as shaded regions. The horizontal dashed line represents no change compared to the baseline levels, and vertical lines represent 24-hour periods.

14 days analysis for self-reported local and systemic reactions after the third dose

We observe a sharp decline in reported local and systemic reactions following three days after the third vaccination dose, and nearly a complete halt within 14 days post-vaccination (Figure S8). Fatigue and headache were the most frequent reactions reported and lasted longer than the other reported reactions.




Figure S8. Most frequent local and systemic reactions reported by participants through the mobile application after the third dose. (A) fatigue, (B) muscle pain, (C) headache, (D) fever, and (E) chills. Error bars represent 90% confidence intervals.

Number of participants receiving each vaccine dose

1,609 participants reported receipt of at least one of the three BNT162b2 mRNA COVID-19 vaccine shots after joining the study. Specifically, out of these 1,609 participants serving as the base cohort for our analyses, 223 received during the study period their first dose, 351 their second dose, and 1,344 their third dose (Table S1).

Table S1. Number of participants receiving each vaccine dose

Dose administered	Number of participants (n)
First dose only	25
Second dose only	127
Third dose only	1,228
All three doses	80
First and second doses	113
First and third doses	5
Second and third doses	31